REGENXBIO Inc.
RGNXNext catalyst
Ranibizumab (LUCENTIS®)
AMD
Get an email about RGNX's next catalysts
Track REGENXBIO (RGNX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 5 more upcoming events in our data (data readout, Phase 3 readout, PDUFA date and more).See the timeline
6 upcoming, 2 past
Ranibizumab (LUCENTIS®) Phase 3 Est. Readout (ATMOSPHERE)
Estimated primary completion for Ranibizumab (LUCENTIS®) trial (NCT04704921) in AMD. Topline data typically follows completion by weeks to months.
SourceData Readout — Surabgene Lomparvovec
For Wet AMD. REGENXBIO announced an investor event on October 20, 2026 to discuss its surabgene lomparvovec clinical program for wet AMD ahead of anticipated topline pivotal data in 4Q 2026. The event will include clinical program overview and perspectives from retina specialists.
SourcePhase 3
Regenxbio announced that its Duchenne muscular dystrophy gene therapy met its primary endpoint in a pivotal study, with the company targeting FDA approval in 2027.
SourceFDA PDUFA Date RGX-121 (accelerated review)
For Hunter syndrome. BLA submitted. AI-extracted from: REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recen
SourceFDA PDUFA Date Regenxbio gene therapy (unnamed)
For Duchenne muscular dystrophy. BLA submitted. AI-extracted from: STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving
SourceBLA Filing — RGX-202
For Duchenne muscular dystrophy. REGENXBIO reported Q2 2026 results with RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026, targeting potential accelerated approval in 2H 2027. Long-term data for surabgene lomparvovec (ABBV-RGX-314) demonstrated durable safety and efficacy.
SourceHow RGNX's past catalysts played out
Market Overview
Stock performance and key metrics
Clinical-stage biotechnology company developing AAV gene therapies
Aflibercept (EYLEA®)
AMD
Local Steroid
Neovascular Age-Related Macular Degeneration (nAMD)
Topical Steroid
Neovascular Age-Related Macular Degeneration (nAMD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Aflibercept (EYLEA®) | Phase 3 | AMD | - | - |
Local Steroid | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) | - | - |
Topical Steroid | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) | - | - |
Wet AMD and Diabetic Retinopathy
1 drug in this indication
Duchenne muscular dystrophy
1 drug in this indication
Diabetic Retinopathy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in REGENXBIO Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in REGENXBIO Inc.'s (RGNX) pipeline across Phase 3, Phase 2. Its lead program is Aflibercept (EYLEA®) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is REGENXBIO Inc.'s next FDA catalyst?→
REGENXBIO Inc.'s (RGNX) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RGNX biotech catalysts?→
Add RGNX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow REGENXBIO Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
